Who
Gopi Shankar
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Larimar Therapeutics.
In numbers
- Trades disclosed
- 10
- Buys
- 1
- Sells
- 0
- Bought
- $19K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 Feb 2023
- Last trade
- 26 Jan 2026
- Last filed
- 27 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jan 2026filed 27 Jan 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —25,637 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —153,822 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —153,822 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —25,637 at $0.00 | filing |
| 22 Jan 2025filed 24 Jan 2025 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —139,838 at $0.00 | filing |
| 22 Jan 2025filed 24 Jan 2025 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —23,306 at $0.00 | filing |
| 17 Jan 2024filed 19 Jan 2024 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 17 Jan 2024filed 19 Jan 2024 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 7 Dec 2023filed 8 Dec 2023 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $19K5,000 at $3.73 | filing |
| 7 Feb 2023filed 9 Feb 2023 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.